Abstract
Vaccines are essential public health tools and play an important role in reducing the burden of infectious diseases in the population. Emerging infectious diseases and outbreaks pose new challenges for vaccine development, requiring the rapid design and production of safe and effective vaccines against diseases with limited resources. Here, we focus on the development of vaccines in broad fields ranging from conventional prophylactic vaccines against infectious diseases to therapeutic vaccines against chronic diseases and cancer providing a comprehensive overview of recent advances in eight different vaccine forms (live attenuated vaccines, inactivated vaccines, polysaccharide and polysaccharide conjugate vaccines, recombinant subunit vaccines, virus-like particle and nanoparticle vaccines, polypeptide vaccines, DNA vaccines, and mRNA vaccines) and the therapeutic vaccines against five solid tumors (lung cancer breast cancer colorectal cancer liver cancer and gastric cancer), three infectious diseases (human immunodeficiency virus, hepatitis B virus and human papillomavirus-induced diseases) and three common chronic diseases (hypertension, diabetes mellitus and dyslipidemia). We aim to provide new insights into vaccine technologies, platforms, applications and understanding of potential next-generation preventive and therapeutic vaccine technologies paving the way for the vaccines design in the future.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Data Availability Statement
All relevant data are within the manuscript.
References
Akhatova, A., Chan, C.K., Azizan, A., and Aimagambetova, G. (2021). The efficacy of therapeutic DNA vaccines expressing the human papillomavirus E6 and E7 oncoproteins for treatment of cervical cancer: systematic review. Vaccines 10, 53.
Al Mahtab, M., Akbar, S.M.F., Aguilar, J.C., Guillen, G., Penton, E., Tuero, A., Yoshida, O., Hiasa, Y., and Onji, M. (2018). Treatment of chronic hepatitis B naïve patients with a therapeutic vaccine containing HBs and HBc antigens (a randomized, open and treatment controlled phase III clinical trial). PLoS ONE 13, e0201236.
Al-Batran, S.E., and Ajani, J.A. (2010). Impact of chemotherapy on quality of life in patients with metastatic esophagogastric cancer. Cancer 116, 2511–2518.
Alexander, J., Sidney, J., Southwood, S., Ruppert, J., Oseroff, C., Maewal, A., Snoke, K., Serra, H.M., Kubo, R.T., Sette, A., et al. (1994). Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity 1, 751–761.
Alfonso, M., Díaz, A., Hernández, A.M., Pérez, A., Rodríguez, E., Bitton, R., Pérez, R., and Vázquez, A.M. (2002). An anti-idiotype vaccine elicits a specific response to N-glycolyl sialic acid residues of glycoconjugates in melanoma patients. J Immunol 168, 2523–2529.
Alfonso, S., Valdés-Zayas, A., Santiesteban, E.R., Flores, Y.I., Areces, F., Hernández, M., Viada, C.E., Mendoza, I.C., Guerra, P.P., García, E., et al. (2014). A randomized, multicenter, placebo-controlled clinical trial of racotumomab-alum vaccine as switch maintenance therapy in advanced non-small cell lung cancer patients. Clin Cancer Res 20, 3660–3671.
Anish, C., Beurret, M., and Poolman, J. (2021). Combined effects of glycan chain length and linkage type on the immunogenicity of glycoconjugate vaccines. npj Vaccines 6, 150.
Antonarakis, E.S., Small, E.J., Petrylak, D.P., Quinn, D.I., Kibel, A.S., Chang, N.N., Dearstyne, E., Harmon, M., Campogan, D., Haynes, H., et al. (2018). Antigen-specific CD8 lytic phenotype induced by sipuleucel-T in hormone-sensitive or castration-resistant prostate cancer and association with overall survival. Clin Cancer Res 24, 4662–4671.
Arab, A., Yazdian-Robati, R., and Behravan, J. (2020). HER2-positive breast cancer immunotherapy: a focus on vaccine development. Arch Immunol Ther Exp 68, 2.
Atsmon, J., Kate-Ilovitz, E., Shaikevich, D., Singer, Y., Volokhov, I., Haim, K.Y., and Ben-Yedidia, T. (2012). Safety and immunogenicity of multimeric-001—a novel universal influenza vaccine. J Clin Immunol 32, 595–603.
Baden, L.R., El Sahly, H.M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S.A., Rouphael, N., Creech, C.B., et al. (2020). Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 384, 403–416.
Baldwin, W.R., Livengood, J.A., Giebler, H.A., Stovall, J.L., Boroughs, K. L., Sonnberg, S., Bohning, K.J., Dietrich, E.A., Ong, Y.T., Danh, H.K., et al. (2018). Purified inactivated zika vaccine candidates afford protection against lethal challenge in mice. Sci Rep 8, 16509.
Barve, M., Bender, J., Senzer, N., Cunningham, C., Greco, F.A., McCune, D., Steis, R., Khong, H., Richards, D., Stephenson, J., et al. (2008). Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer. J Clin Oncol 26, 4418–4425.
Boni, C., Janssen, H.L.A., Rossi, M., Yoon, S.K., Vecchi, A., Barili, V., Yoshida, E.M., Trinh, H., Rodell, T.C., Laccabue, D., et al. (2019). Combined GS-4774 and tenofovir therapy can improve HBV-specific T-cell responses in patients with chronic hepatitis. Gastroenterology 157, 227–241.e7.
Boyoglu-Barnum, S., Ellis, D., Gillespie, R.A., Hutchinson, G.B., Park, Y. J., Moin, S.M., Acton, O.J., Ravichandran, R., Murphy, M., Pettie, D., et al. (2021). Quadrivalent influenza nanoparticle vaccines induce broad protection. Nature 592, 623–628.
Brouwer, P.J.M., Antanasijevic, A., Berndsen, Z., Yasmeen, A., Fiala, B., Bijl, T.P.L., Bontjer, I., Bale, J.B., Sheffler, W., Allen, J.D., et al. (2019). Enhancing and shaping the immunogenicity of native-like HIV-1 envelope trimers with a two-component protein nanoparticle. Nat Commun 10, 4272.
Brouwer, P.J.M., Brinkkemper, M., Maisonnasse, P., Dereuddre-Bosquet, N., Grobben, M., Claireaux, M., de Gast, M., Marlin, R., Chesnais, V., Diry, S., et al. (2021). Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection. Cell 184, 1188–1200. e19.
Brown, M.J., Coltart, J., Gunewardena, K., Ritter, J.M., Auton, T.R., and Glover, J.F. (2004). Randomized double-blind placebo-controlled study of an angiotensin immunotherapeutic vaccine (PMD3117) in hypertensive subjects. Clin Sci 107, 167–173.
Buonaguro, L., Mayer, A., Loeffler, M., Missel, S., and Singh, H. (2020). Abstract LB-094: hepavac-101 first-in-man clinical trial of a multi-peptide-based vaccine for hepatocellular carcinoma. In: Proceedings: AACR Annual Meeting 2020. Philadelphia, PA.
Cafri, G., Gartner, J.J., Zaks, T., Hopson, K., Levin, N., Paria, B.C., Parkhurst, M.R., Yossef, R., Lowery, F.J., Jafferji, M.S., et al. (2020). mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer. J Clin Invest 130, 5976–5988.
Cai, Z., Su, X., Qiu, L., Li, Z., Li, X., Dong, X., Wei, F., Zhou, Y., Luo, L., Chen, G., et al. (2021). Personalized neoantigen vaccine prevents postoperative recurrence in hepatocellular carcinoma patients with vascular invasion. Mol Cancer 20, 164.
Carmichael, M.G., Benavides, L.C., Holmes, J.P., Gates, J.D., Mittendorf, E.A., Ponniah, S., and Peoples, G.E. (2010). Results of the first phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients. Cancer 116, 292–301.
Cavelti-Weder, C., Timper, K., Seelig, E., Keller, C., Osranek M., Lässing, U., Spohn, G., Maurer, P., Müller, P., Jennings, G.T., et al. (2016). Development of an Interleukin-1β Vaccine in Patients with Type 2 Diabetes. Mol Ther 24, 1003–1012.
Cech, P.G., Aebi, T., Abdallah, M.S., Mpina, M., Machunda, E.B., Westerfeld, N., Stoffel, S.A., Zurbriggen, R., Pluschke, G., Tanner, M., et al. (2011). Virosome-formulated Plasmodium falciparum AMA-1 & CSP Derived peptides as malaria vaccine: randomized Phase 1b trial in semi-immune adults & children. PLoS ONE 6, e22273.
Chen, G.L., Li, X.F., Dai, X.H., Li, N., Cheng, M.L., Huang, Z., Shen, J., Ge, Y.H., Shen, Z.W., Deng, Y.Q., et al. (2022a). Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Microbe 3, e193–e202.
Chen, N., Xia, P., Li, S., Zhang, T., Wang, T.T., and Zhu, J. (2017). RNA sensors of the innate immune system and their detection of pathogens. IUBMB Life 69, 297–304.
Chen, S.M.Y., Wong, Y.C., Yim, L.Y., Zhang, H., Wang, H., Lui, G.C.Y., Li, X., Tang, X., Cheng, L., Du, Y., et al. (2022b). Enhanced cross-reactive and polyfunctional effector-memory T cell responses by ICVAX—a human PD1-based bivalent HIV-1 Gag-p41 mosaic DNA vaccine. J Virol 96, e0216121.
Choi, Y.J., Hur, S.Y., Kim, T.J., Hong, S.R., Lee, J.K., Cho, C.H., Park, K. S., Woo, J.W., Sung, Y.C., Suh, Y.S., et al. (2020). A phase II, prospective, randomized, multicenter, open-label study of GX-188E, an HPV DNA vaccine, in patients with cervical intraepithelial neoplasia 3. Clin Cancer Res 26, 1616–1623.
Clifton, G.T., Hale, D., Vreeland, T.J., Hickerson, A.T., Litton, J.K., Alatrash, G., Murthy, R.K., Qiao, N., Philips, A.V., Lukas, J.J., et al. (2020). Results of a randomized phase IIb trial of nelipepimut-S + trastuzumab versus trastuzumab to prevent recurrences in patients with high-risk HER2 low-expressing breast cancer. Clin Cancer Res 26, 2515–2523.
Clifton, G.T., Peoples, G.E., and Mittendorf, E.A. (2016). The development and use of the E75 (HER2 369–377) peptide vaccine. Future Oncol 12, 1321–1329.
Corti, C., Giachetti, P.P.M.B., Eggermont, A.M.M., Delaloge, S., and Curigliano, G. (2022). Therapeutic vaccines for breast cancer: has the time finally come? Eur J Cancer 160, 150–174.
Crank, M.C., Ruckwardt, T.J., Chen, M., Morabito, K.M., Phung, E., Costner, P.J., Holman, L.S.A., Hickman, S.P., Berkowitz, N.M., Gordon, I.J., et al. (2019). A proof of concept for structure-based vaccine design targeting RSV in humans. Science 365, 505–509.
Da Silva, D.M., Skeate, J.G., Chavez-Juan, E., Lühen, K.P., Wu, J.M., Wu, C.M., Kast, W.M., and Hwang, K.K. (2019). Therapeutic efficacy of a human papillomavirus type 16 E7 bacterial exotoxin fusion protein adjuvanted with CpG or GPI-0100 in a preclinical mouse model for HPV-associated disease. Vaccine 37, 2915–2924.
Dai, L., Zheng, T., Xu, K., Han, Y., Xu, L., Huang, E., An, Y., Cheng, Y., Li, S., Liu, M., et al. (2020). A universal design of betacoronavirus vaccines against COVID-19, MERS, and SARS. Cell 182, 722–733.e11.
Dai, Y., Chen, X., Song, X., Chen, X., Ma, W., Lin, J., Wu, H., Hu, X., Zhou, Y., Zhang, H., et al. (2019). Immunotherapy of endothelin-1 receptor type A for pulmonary arterial hypertension. J Am College Cardiol 73, 2567–2580.
Darrow, J.J., and Kesselheim, A.S. (2015). A new wave of vaccines for non-communicable diseases: what are the regulatory challenges? Food Drug Law J 70, 243–258.
Díaz, A., Alfonso, M., Alonso, R., Saurez, G., Troche, M., Catalá, M., Díaz, R.M., Pérez, R., and Vázquez, A.M. (2003). Immune responses in breast cancer patients immunized with an anti-idiotype antibody mimicking NeuGc-containing gangliosides. Clin Immunol 107, 80–89.
Diaz-Arévalo, D., and Zeng, M. (2020). Nanoparticle-based vaccines: opportunities and limitations. Nanopharmaceuticals 1, 135–150.
Dores, G.M., Bryant-Genevier, M., and Perez-Vilar, S. (2019). Adverse events associated with the use of sipuleucel-T reported to the US Food and Drug Administration’s Adverse Event Reporting System, 2010–2017. JAMA Netw Open 2, e199249.
Downham, M.R., Auton, T.R., Rosul, A., Sharp, H.L., Sjöström, L., Rushton, A., Richards, J.P., Mant, T.G.K., Gardiner, S.M., Bennett, T., et al. (2003). Evaluation of two carrier protein-angiotensin I conjugate vaccines to assess their future potential to control high blood pressure (hypertension) in man. Br J Clin Pharmacol 56, 505–512.
Dunkle, L.M., Kotloff, K.L., Gay, C.L., Áñez, G., Adelglass, J.M., Barrat Hernández, A.Q., Harper, W.L., Duncanson, D.M., McArthur, M.A., Florescu, D.F., et al. (2021). Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico. N. Engl J Med 386, 531–543.
Emens, L.A., Asquith, J.M., Leatherman, J.M., Kobrin, B.J., Petrik, S., Laiko, M., Levi, J., Daphtary, M.M., Biedrzycki, B., Wolff, A.C., et al. (2009). Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. J Clin Oncol 27, 5911–5918.
Enotarpi, J., Tontini, M., Balocchi, C., van der Es, D., Auberger, L., Balducci, E., Carboni, F., Proietti, D., Casini, D., Filippov, D.V., et al. (2020). A stabilized glycomimetic conjugate vaccine inducing protective antibodies against Neisseria meningitidis serogroup A. Nat Commun 11, 4434.
Espinar-Buitrago, M., and Muñoz-Fernández, M.A. (2022). New approaches to dendritic cell-based therapeutic vaccines against HIV-1 infection. Front Immunol 12, 719664.
Fan, A., Wang, B., Wang, X., Nie, Y., Fan, D., Zhao, X., and Lu, Y. (2021). Immunotherapy in colorectal cancer: current achievements and future perspective. Int J Biol Sci 17, 3837–3849.
Felip, E., Besse, B., Dziadziuszko, R., Dols, M.C., Denis, F., García-Campelo, M.R., Debieuvre, D., Catino, A., Moran Bueno, M.T., Madroszyk Flandin, A.C., et al. (2019). ATALANTE-1 randomized phase III trial, OSE-2101 versus standard treatment as second or third-line in HLA-A2 positive advanced non-small cell lung cancer (NSCLC) patients. Ann Oncol 30, v658.
Fontaine, H., Chazallon, C., Mancini-Bourgine, M., Lebray, P., Buffet, C., Kahi, S., Godon, O., Meritet, J.F., Saldi, Y., Michel, M.L., et al. (2011). 1367 Relapse after analogues treatment discontinuation is not prevented by dna vaccination in chronic hepatitis b (ANRS HB 02 VAC-ADN). J Hepatol 54, S542.
Freeman-Keller, M., Goldman, J., and Gray, J. (2015). Vaccine immunotherapy in lung cancer: clinical experience and future directions. Pharmacol Ther 153, 1–9.
Fukami, H., Morinaga, J., Nakagami, H., Hayashi, H., Okadome, Y., Matsunaga, E., Kadomatsu, T., Horiguchi, H., Sato, M., Sugizaki, T., et al. (2021). Vaccine targeting ANGPTL3 ameliorates dyslipidemia and associated diseases in mouse models of obese dyslipidemia and familial hypercholesterolemia. Cell Rep Med 2, 100446.
Gajdosik, Z. (2014). Racotumomab: a novel anti-idiotype monoclonal antibody vaccine for the treatment of cancer. Drugs Today 50, 301.
Gardner, T.A., Elzey, B.D., and Hahn, N.M. (2012). Sipuleucel-T (Provenge) autologous vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate cancer. Hum Vaccines Immunother 8, 534–539.
Gay, C.L., DeBenedette, M.A., Tcherepanova, I.Y., Gamble, A., Lewis, W. E., Cope, A.B., Kuruc, J.A.D., McGee, K.S., Kearney, M.F., Coffin, J. M., et al. (2018). Immunogenicity of AGS-004 dendritic cell therapy in patients treated during acute HIV infection. AIDS Res Hum Retroviruses 34, 111–122.
Gebre, M.S., Brito, L.A., Tostanoski, L.H., Edwards, D.K., Carfi, A., and Barouch, D.H. (2021). Novel approaches for vaccine development. Cell 184, 1589–1603.
Ghattas, M., Dwivedi, G., Lavertu, M., and Alameh, M.G. (2021). Vaccine technologies and platforms for infectious diseases: current progress, challenges, and opportunities. Vaccines 9, 1490.
Giaccone, G., Felip, E., Cobo, M., Campelo, R.G., Denis, F., Quoix, E., Madroszyk, A., Debieuvre, D., Hilgers, W., Moran, T., et al. (2020). 1260MO Activity of OSE-2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (ICI): Step 1 results of phase III ATALANTE-1 randomised trial. Ann Oncol 31, S814–S815.
Gilliam, A.D., Watson, S.A., Henwood, M., McKenzie, A.J., Humphreys, J. E., Elder, J., Iftikhar, S.Y., Welch, N., Fielding, J., Broome, P., et al. (2004). A phase II study of G17DT in gastric carcinoma. Eur J Surg Oncol 30, 536–543.
Gong, R., Ding, C., Hu, J., Lu, Y., Liu, F., Mann, E., Xu, F., Cohen, M.B., and Luo, M. (2011). Role for the membrane receptor guanylyl cyclase-C in attention deficiency and hyperactive behavior. Science 333, 1642–1646.
González, G., Crombet, T., Catalá, M., Mirabal, V., Hernández, J.C., González, Y., Marinello, P., Guillén, G., and Lage, A. (1998). A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: report of a pilot clinical trial. Ann Oncol 9, 431–435.
Gonzalez, G., Crombet, T., Torres, F., Catala, M., Alfonso, L., Osorio, M., Neninger, E., Garcia, B., Mulet, A., Perez, R., et al. (2003). Epidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy. Ann Oncol 14, 461–466.
González-Perera, I., Gutiérrez-Nicolás, F., Nazco-Casariego, G.J., Ramos-Díaz, R., Hernández-San Gil, R., Pérez-Pérez, J.A., González García, J., and González De La Fuente, G.A. (2017). 5-fluorouracil toxicity in the treatment of colon cancer associated with the genetic polymorphism 2846 A>G (rs67376798). J Oncol Pharm Pract 23, 396–398.
Groenke, N., Trimpert, J., Merz, S., Conradie, A.M., Wyler, E., Zhang, H., Hazapis, O.G., Rausch, S., Landthaler, M., Osterrieder, N., et al. (2020). Mechanism of virus attenuation by codon pair deoptimization. Cell Rep 31, 107586.
Halfmann, P.J., Castro, A., Loeffler, K., Frey, S.J., Chiba, S., Kawaoka, Y., and Kane, R.S. (2021). Potent neutralization of SARS-CoV-2 including variants of concern by vaccines presenting the receptor-binding domain multivalently from nanoscaffolds. Bioeng Transl Med 6, e10253.
Hatz, C.F.R., Bally, B., Rohrer, S., Steffen, R., Kramme, S., Siegrist, C.A., Wacker, M., Alaimo, C., and Fonck, V.G. (2015). Safety and immunogenicity of a candidate bioconjugate vaccine against Shigella dysenteriae type 1 administered to healthy adults: a single blind, partially randomized Phase I study. Vaccine 33, 4594–4601.
Heitmann, J.S., Bilich, T., Tandler, C., Nelde, A., Maringer, Y., Marconato, M., Reusch, J., Jäger, S., Denk, M., Richter, M., et al. (2022). A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity. Nature 601, 617–622.
Hernández, A.M., Toledo, D., Martínez, D., Griñán, T., Brito, V., Macías, A., Alfonso, S., Rondón, T., Suárez, E., Vázquez, A.M., et al. (2008). Characterization of the antibody response against NeuGcGM3 ganglioside elicited in non-small cell lung cancer patients immunized with an anti-idiotype antibody. J Immunol 181, 6625–6634.
Higano, C.S., Armstrong, A.J., Sartor, A.O., Vogelzang, N.J., Kantoff, P. W., McLeod, D.G., Pieczonka, C.M., Penson, D.F., Shore, N.D., Vacirca, J., et al. (2019). Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer. Cancer 125, 4172–4180.
Hirsch, F.R., Scagliotti, G.V., Mulshine, J.L., Kwon, R., Curran Jr, W.J., Wu, Y.L., and Paz-Ares, L. (2017). Lung cancer: current therapies and new targeted treatments. Lancet 389, 299–311.
Horng, J.H., Lin, W.H., Wu, C.R., Lin, Y.Y., Wu, L.L., Chen, D.S., and Chen, P.J. (2020). HBV X protein-based therapeutic vaccine accelerates viral antigen clearance by mobilizing monocyte infiltration into the liver in HBV carrier mice. J Biomed Sci 27, 70.
Hu, Y.M., Guo, M., Li, C.G., Chu, K., He, W.G., Zhang, J., Gu, J.X., Li, J., Zhao, H., Wu, X.H., et al. (2020). Immunogenicity noninferiority study of 2 doses and 3 doses of an Escherichia coli-produced HPV bivalent vaccine in girls vs. 3 doses in young women. Sci China Life Sci 63, 582–591.
Hubbard, J.M., Cremolini, C., Graham, R.P., Moretto, R., Mitchell, J.L., Wessling, J., Toke, E.R., Csiszovszki, Z., Lőrincz, O., Molnar, L., et al. (2020). Evaluation of safety, immunogenicity, and preliminary efficacy of PolyPEPI1018 off-the-shelf vaccine with fluoropyrimidine/bevacizumab maintenance therapy in metastatic colorectal cancer (mCRC) patients. J Clin Oncol 38, 4048.
Ikeda, M., Okusaka, T., Ohno, I., Mitsunaga, S., Kondo, S., Ueno, H., Morizane, C., Gemmoto, K., Suna, H., Ushida, Y., et al. (2021). Phase I studies of peptide vaccine cocktails derived from GPC3, WDRPUH and NEIL3 for advanced hepatocellular carcinoma. Immunotherapy 13, 371–385.
Jardine, J., Julien, J.P., Menis, S., Ota, T., Kalyuzhniy, O., McGuire, A., Sok, D., Huang, P.S., MacPherson, S., Jones, M., et al. (2013). Rational HIV immunogen design to target specific germline B cell receptors. Science 340, 711–716.
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., and Thun, M.J. (2007). Cancer statistics, 2007. CA-Cancer J Clin 57, 43–66.
Jin, H., Li, D., Lin, M.H., Li, L., and Harrich, D. (2020). Tat-based therapies as an adjuvant for an HIV-1 functional cure. Viruses 12, 415.
Jones, B. (2015). Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. Ann Clin Biochem 52, 518.
Joyce, M.G., Chen, W.H., Sankhala, R.S., Hajduczki, A., Thomas, P.V., Choe, M., Martinez, E.J., Chang, W.C., Peterson, C.E., Morrison, E.B., et al. (2021). SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity. Cell Rep 37, 110143.
Kanehira, M., Harada, Y., Takata, R., Shuin, T., Miki, T., Fujioka, T., Nakamura, Y., and Katagiri, T. (2007). Involvement of upregulation of DEPDC1 (DEP domain containing 1) in bladder carcinogenesis. Oncogene 26, 6448–6455.
Kanekiyo, M., Wei, C.J., Yassine, H.M., McTamney, P.M., Boyington, J.C., Whittle, J.R.R., Rao, S.S., Kong, W.P., Wang, L., and Nabel, G.J. (2013). Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature 499, 102–106.
Kang, Y.K., Boku, N., Satoh, T., Ryu, M.H., Chao, Y., Kato, K., Chung, H. C., Chen, J.S., Muro, K., Kang, W.K., et al. (2017). Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538–12, ATTRACTION-2): a randomised, doubleblind, placebo-controlled, phase 3 trial. Lancet 390, 2461–2471.
Kantoff, P.W., Higano, C.S., Shore, N.D., Berger, E.R., Small, E.J., Penson, D.F., Redfern, C.H., Ferrari, A.C., Dreicer, R., Sims, R.B., et al. (2010). Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363, 411–422.
Karayiannis, P. (2017). Hepatitis B virus: virology, molecular biology, life cycle and intrahepatic spread. Hepatol Int 11, 500–508.
Karikó, K., Buckstein, M., Ni, H., and Weissman, D. (2005). Suppression of RNA recognition by toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23, 165–175.
Karikó, K., Ni, H., Capodici, J., Lamphier, M., and Weissman, D. (2004). mRNA is an endogenous ligand for toll-like receptor 3. J Biol Chem 279, 12542–12550.
Kawakami, R., Nozato, Y., Nakagami, H., Ikeda, Y., Shimamura, M., Yoshida, S., Sun, J., Kawano, T., Takami, Y., Noma, T., et al. (2018). Development of vaccine for dyslipidemia targeted to a proprotein convertase subtilisin/kexin type 9 (PCSK9) epitope in mice. PLoS ONE 13, e0191895.
Keskin, D.B., Anandappa, A.J., Sun, J., Tirosh, I., Mathewson, N.D., Li, S., Oliveira, G., Giobbie-Hurder, A., Felt, K., Gjini, E., et al. (2019). Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature 565, 234–239.
Khan, S.T., Montroy, J., Forbes, N., Bastin, D., Kennedy, M.A., Diallo, J.S., Kekre, N., Fergusson, D.A., Lalu, M., and Auer, R.C. (2020). Safety and efficacy of autologous tumour cell vaccines as a cancer therapeutic to treat solid tumours and haematological malignancies: a meta-analysis protocol for two systematic reviews. BMJ Open 10, e034714.
Kheirollahpour, M., Mehrabi, M., Dounighi, N.M., Mohammadi, M., and Masoudi, A. (2020). Nanoparticles and vaccine development. PNT 8, 6–21.
Khobragade, A., Bhate, S., Ramaiah, V., Deshpande, S., Giri, K., Phophle, H., Supe, P., Godara, I., Revanna, R., Nagarkar, R., et al. (2022). Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India. Lancet 399, 1313–1321.
Kim, C., Kim, J.D., and Seo, S.U. (2022). Nanoparticle and virus-like particle vaccine approaches against SARS-CoV-2. J Microbiol 60, 335–346.
Koriyama, H., Nakagami, H., Nakagami, F., Osako, M.K., Kyutoku, M., Shimamura, M., Kurinami, H., Katsuya, T., Rakugi, H., and Morishita, R. (2015). Long-term reduction of high blood pressure by angiotensin II DNA vaccine in spontaneously hypertensive rats. Hypertension 66, 167–174.
Kremsner, P.G., Ahuad Guerrero, R.A., Arana-Arri, E., Aroca Martinez, G. J., Bonten, M., Chandler, R., Corral, G., De Block, E.J.L., Ecker, L., Gabor, J.J., et al. (2022). Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial. Lancet Infect Dis 22, 329–340.
Kristensen, L.S., Andersen, M.S., Stagsted, L.V.W., Ebbesen, K.K., Hansen, T.B., and Kjems, J. (2019). The biogenesis, biology and characterization of circular RNAs. Nat Rev Genet 20, 675–691.
Kühtreiber, W.M., Tran, L., Kim, T., Dybala, M., Nguyen, B., Plager, S., Huang, D., Janes, S., Defusco, A., Baum, D., et al. (2018). Long-term reduction in hyperglycemia in advanced type 1 diabetes: the value of induced aerobic glycolysis with BCG vaccinations. npj Vaccines 3, 23.
Lal, H., Cunningham, A.L., Godeaux, O., Chlibek, R., Diez-Domingo, J., Hwang, S.J., Levin, M.J., McElhaney, J.E., Poder, A., Puig-Barberà, J., et al. (2015). Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N., Engl J Med 372, 2087–2096.
Leal, L., Couto, E., Sánchez-Palomino, S., Climent, N., Fernández, I., Miralles, L., Romero, Y., González, T., Maleno, M.J., Paño, B., et al. (2021). Effect of intranodally administered dendritic cell-based HIV vaccine in combination with pegylated interferon α-2a on viral control following ART discontinuation: a phase 2A randomized clinical trial. Front Immunol 12, 767370.
Lesinski, G.B., and Westerink, M.A.J. (2001). Novel vaccine strategies to T-independent antigens. J Microbiol Methods 47, 135–149.
Lévy, Y., Lacabaratz, C., Lhomme, E., Wiedemann, A., Bauduin, C., Fenwick, C., Foucat, E., Surenaud, M., Guillaumat, L., Boilet, V., et al. (2021). A randomized placebo-controlled efficacy study of a prime boost therapeutic vaccination strategy in HIV-1-infected individuals: VRI02 ANRS 149 LIGHT phase II trial. J Virol 95, e02165–20.
Li, C., Yan, X., Wu, D., Zhang, K., Liang, X., Pan, Y., Zhou, Y., Chen, F., Chen, X., Yang, S., et al. (2019). Vaccine targeted alpha 1D-adrenergic receptor for hypertension. Hypertension 74, 1551–1562.
Li, H., Zhang, Y., Li, D., Deng, Y.Q., Xu, H., Zhao, C., Liu, J., Wen, D., Zhao, J., Li, Y., et al. (2021). Enhanced protective immunity against SARS-CoV-2 elicited by a VSV vector expressing a chimeric spike protein. Sig Transduct Target Ther 6, 389.
Li, Y., Cao, H., Li, Y., Li, Z., Wei, X., Jiao, R., Cheng, P., Liu, X., Ma, Y., Xing, Y., et al. (2017a). Construction of a novel vaccine by conjugating a B-cell epitope of DPP4 to peptide IA2(5)-P2–1 to significantly control type 1 diabetes in NOD mice. Vaccine 35, 7187–7197.
Li, Z., Fang, J., Jiao, R., Wei, X., Ma, Y., Liu, X., Cheng, P., and Li, T. (2017b). A novel multi-epitope vaccine based on Dipeptidyl Peptidase 4 prevents streptozotocin-induced diabetes by producing anti-DPP4 antibody and immunomodulatory effect in C57BL/6J mice. Biomed pharmacoTher 89, 1467–1475.
Li, Z., Song, S., He, M., Wang, D., Shi, J., Liu, X., Li, Y., Chi, X., Wei, S., Yang, Y., et al. (2018). Rational design of a triple-type human papillomavirus vaccine by compromising viral-type specificity. Nat Commun 9, 5360.
Liang, F., Lindgren, G., Lin, A., Thompson, E.A., Ols, S., Röhss, J., John, S., Hassett, K., Yuzhakov, O., Bahl, K., et al. (2017). Efficient targeting and activation of antigen-presenting cells in vivo after modified mRNA vaccine administration in rhesus macaques. Mol Ther 25, 2635–2647.
Lim, H., In, H.J., Lee, J.A., Sik Yoo, J., Lee, S.W., Chung, G.T., Choi, Y.K., Chung, J.K., Cho, S.J., and Lee, J.W. (2018). The immunogenicity and protection effect of an inactivated coxsackievirus A6, A10, and A16 vaccine against hand, foot, and mouth disease. Vaccine 36, 3445–3452.
Lindgren, G., Ols, S., Liang, F., Thompson, E.A., Lin, A., Hellgren, F., Bahl, K., John, S., Yuzhakov, O., Hassett, K.J., et al. (2017). Corrigendum: induction of robust B cell responses after influenza mRNA vaccination is accompanied by circulating hemagglutininspecific ICOS+ PD-1+ CXCR3+ T follicular helper cells. Front Immunol 10, 614.
Liu, Y., Li, T., Liu, Y., Hao, Y., Wang, J., Wu, Y., Liang, H., Ren, L., Hong, K., Xu, J., et al. (2015). Development of HIV-1 vaccines based on replication competent Tiantan vaccinia vector in China. Lancet 386, S10.
Lu, K., Su, B., and Meng, X. (2018). Recent advances in the development of vaccines for diabetes, hypertension, and atherosclerosis. J Diabetes Res 2018, 1–8.
Lu, L., Zhang, H., Zhan, M., Jiang, J., Yin, H., Dauphars, D.J., Li, S.Y., Li, Y., and He, Y.W. (2020). Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development? Sci China Life Sci 63, 1833–1849.
Malonis, R.J., Lai, J.R., and Vergnolle, O. (2020). Peptide-based vaccines: current progress and future challenges. Chem Rev 120, 3210–3229.
Marcandalli, J., Fiala, B., Ols, S., Perotti, M., de van der Schueren, W., Snijder, J., Hodge, E., Benhaim, M., Ravichandran, R., Carter, L., et al. (2019). Induction of potent neutralizing antibody responses by a designed protein nanoparticle vaccine for respiratory syncytial virus. Cell 176, 1420–1431.e17.
Marquina, G., Waki, H., Fernandez, L.E., Kon, K., Carr, A., Valiente, O., Perez, R., and Ando, S. (1996). Gangliosides expressed in human breast cancer. Cancer Res 56, 5165–5171.
Masuzawa, T., Fujiwara, Y., Okada, K., Nakamura, A., Takiguchi, S., Nakajima, K., Miyata, H., Yamasaki, M., Kurokawa, Y., Osawa, R., et al. (2012). Phase I/II study of S-1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancer. Int J Oncol 41, 1297–1304.
Matić, Z., and Šantak, M. (2022). Current view on novel vaccine technologies to combat human infectious diseases. Appl Microbiol Biotechnol 106, 25–56.
Merlo, V., Longo, M., Novello, S., and Scagliotti, G.V. (2011). EGFR pathway in advanced non-small cell lung cancer. Front Biosci S3, 501–517.
Mittendorf, E.A., Ardavanis, A., Symanowski, J., Murray, J.L., Shumway, N.M., Litton, J.K., Hale, D.F., Perez, S.A., Anastasopoulou, E.A., Pistamaltzian, N.F., et al. (2016). Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence. Ann Oncol 27, 1241–1248.
Momtazi-Borojeni, A.A., Jaafari, M.R., Badiee, A., Banach, M., and Sahebkar, A. (2019). Therapeutic effect of nanoliposomal PCSK9 vaccine in a mouse model of atherosclerosis. BMC Med 17, 223.
Monteiro, M.P. (2014). Obesity vaccines. Hum Vaccines Immunother 10, 887–895.
Muro, K., Chung, H.C., Shankaran, V., Geva, R., Catenacci, D., Gupta, S., Eder, J.P., Golan, T., Le, D.T., Burtness, B., et al. (2016). Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol 17, 717–726.
Nakagami, H., Ishihama, T., Daikyoji, Y., Sasakura, C., Yamada, E., and Morishita, R. (2022). Brief report on a phase I/IIa study to assess the safety, tolerability, and immune response of AGMG0201 in patients with essential hypertension. Hypertens Res 45, 61–65.
Nakagawa, H., Mizukoshi, E., Kobayashi, E., Tamai, T., Hamana, H., Ozawa, T., Kishi, H., Kitahara, M., Yamashita, T., Arai, K., et al. (2017). Association between high-avidity T-cell receptors, induced by α-fetoprotein-derived peptides, and anti-tumor effects in patients with hepatocellular carcinoma. Gastroenterology 152, 1395–1406.e10.
Neninger, E., Díaz, R.M., de la Torre, A., Rives, R., Díaz, A., Saurez, G., Gabri, M.R., Alonso, D.F., Wilkinson, B., Alfonso, A.M., et al. (2007). Active immunotherapy with 1E10 anti-idiotype vaccine in patients with small cell lung cancer: report of a phase I trial. Cancer Biol Ther 6, 145–150.
Neninger Vinageras, E., de la Torre, A., Osorio Rodríguez, M., CataláFerrer, M., Bravo, I., Mendoza del Pino, M., Abreu Abreu, D., Acosta Brooks, S., Rives, R., del Castillo Carrillo, C., et al. (2008). Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer. J Clin Oncol 26, 1452–1458.
Ogura, A., Konishi, T., Cunningham, C., Garcia-Aguilar, J., Iversen, H., Toda, S., Lee, I.K., Lee, H.X., Uehara, K., Lee, P., et al. (2019). Neoadjuvant (Chemo)radiotherapy with total mesorectal excision only is not sufficient to prevent lateral local recurrence in enlarged nodes: results of the multicenter lateral node study of patients with low cT3/4 rectal cancer. J Clin Oncol 37, 33–43.
Okitsu, S.L., Silvie, O., Westerfeld, N., Curcic, M., Kammer, A.R., Mueller, M.S., Sauerwein, R.W., Robinson, J.A., Genton, B., Mazier, D., et al. (2007). A virosomal malaria peptide vaccine elicits a long-lasting sporozoite-inhibitory antibody response in a phase 1a clinical trial. PLoS ONE 2, e1278.
Olotu, A., Fegan, G., Wambua, J., Nyangweso, G., Leach, A., Lievens, M., Kaslow, D.C., Njuguna, P., Marsh, K., and Bejon, P. (2016). Seven-year efficacy of RTS,S/AS01 malaria vaccine among young african children. N Engl J Med 374, 2519–2529.
Page, I.H., Helmer, O.M., Kohlstaedt, K.G., Fouts, P.J., and Kempf, G.F. (1941). Reduction of arterial blood pressure of hypertensive patients and animals with extracts of kidneys. J Exp Med 73, 7–41.
Pan, Y., Zhou, Y., Wu, H., Chen, X., Hu, X., Zhang, H., Zhou, Z., Qiu, Z., and Liao, Y. (2017). A therapeutic peptide vaccine against PCSK9. Sci Rep 7, 12534.
Park, J.W., Melisko, M.E., Esserman, L.J., Jones, L.A., Wollan, J.B., and Sims, R. (2007). Treatment with autologous antigen-presenting cells activated with the HER-2-based antigen lapuleucel-T: results of a phase I study in immunologic and clinical activity in HER-2-overexpressing breast cancer. J Clin Oncol 25, 3680–3687.
Pizza, M., Scarlato, V., Masignani, V., Giuliani, M.M., Arico, B., Comanducci, M., Jennings, G.T., Baldi, L., Bartolini, E., Capecchi, B., et al. (2000). Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 287, 1816–1820.
Polack, F.P., Thomas, S.J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J.L., Pérez Marc, G., Moreira, E.D., Zerbini, C., et al. (2020). Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N., Engl J Med 383, 2603–2615.
Pollard, A.J., and Bijker, E.M. (2021). A guide to vaccinology: from basic principles to new developments. Nat Rev Immunol 21, 83–100.
Qian, C., Liu, X., Xu, Q., Wang, Z., Chen, J., Li, T., Zheng, Q., Yu, H., Gu, Y., Li, S., et al. (2020). Recent progress on the versatility of virus-like particles. Vaccines 8, 139.
Qian, C., Yang, Y., Xu, Q., Wang, Z., Chen, J., Chi, X., Yu, M., Gao, F., Xu, Y., Lu, Y., et al. (2022) Characterization of an Escherichia coli-derived triple-type chimeric vaccine against human papillomavirus types 39, 68 and 70. npj Vaccines 7, 134.
Qin, S., Bai, Y., Lim, H.Y., Thongprasert, S., Chao, Y., Fan, J., Yang, T.S., Bhudhisawasdi, V., Kang, W.K., Zhou, Y., et al. (2013). Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol 31, 3501–3508.
Qu, L., Yi, Z., Shen, Y., Lin, L., Chen, F., Xu, Y., Wu, Z., Tang, H., Zhang, X., Tian, F., et al. (2022). Circular RNA vaccines against SARS-CoV-2 and emerging variants. Cell 185, 1728–1744.e16.
Rajoriya, N., Combet, C., Zoulim, F., and Janssen, H.L.A. (2017). How viral genetic variants and genotypes influence disease and treatment outcome of chronic hepatitis B. Time for an individualised approach? J Hepatol 67, 1281–1297.
Ramos da Silva, J., Ramos Moreno, A.C., Silva Sales, N., de Oliveira Silva, M., Aps, L.R.M.M., Porchia, B.F.M.M., Bitencourt Rodrigues, K., Cestari Moreno, N., Venceslau-Carvalho, A.A., Menck, C.F.M., et al. (2021). A therapeutic DNA vaccine and gemcitabine act synergistically to eradicate HPV-associated tumors in a preclinical model. Oncoimmunology 10, 1949896.
Ramos, T.C., Vinageras, E.N., CataláFerrer, M., García Verdecia, B., Leonard Rupalé, I., Martínez Pérez, L., González Marinello, G., Pérez Rodríguez, R., and Lage Dávila, A. (2006). Treatment of NSCLC patients with an EGF-based cancer vaccine: report of a Phase I trial. Cancer Biol Ther 5, 145–149.
Rappuoli, R., De Gregorio, E., and Costantino, P. (2019). On the mechanisms of conjugate vaccines. Proc Natl Acad Sci USA 116, 14–16.
Riddle Mark, S., Kaminski Robert, W., Di Paolo, C., Porter Chad, K., Gutierrez Ramiro, L., Clarkson Kristen, A., Weerts Hailey, E., Duplessis, C., Castellano, A., Alaimo, C., et al. (2016). Safety and immunogenicity of a candidate bioconjugate vaccine against shigella flexneri 2a administered to healthy adults: a single-blind, randomized phase I study. Clin Vacc Immunol 23, 908–917.
Roberts, D.M., Kearney, J.B., Johnson, J.H., Rosenberg, M.P., Kumar, R., and Bautch, V.L. (2004). The vascular endothelial growth factor (VEGF) receptor Flt-1 (VEGFR-1) modulates Flk-1 (VEGFR-2) signaling during blood vessel formation. Am J Pathol 164, 1531–1535.
Robinson, J.G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E.S., Langslet, G., Raal, F.J., El Shahawy, M., et al. (2015). Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N., Engl J Med 372, 1489–1499.
Rodrigues, M.Q., Alves, P.M., and Roldão, A. (2021). Functionalizing ferritin nanoparticles for vaccine development. Pharmaceutics 13, 1621.
Rodriguez, P.C., Neninger, E., García, B., Popa, X., Viada, C., Luaces, P., González, G., Lage, A., Montero, E., and Crombet, T. (2011). Safety, immunogenicity and preliminary efficacy of multiple-site vaccination with an Epidermal Growth Factor (EGF) based cancer vaccine in advanced non small cell lung cancer (NSCLC) patients. J Immune Based Ther Vaccines 9, 7.
Sanchez, L., Muchene, L., Lorenzo-Luaces, P., Viada, C., Rodriguez, P.C., Alfonso, S., Crombet, T., Neninger, E., Shkedy, Z., and Lage, A. (2018). Differential effects of two therapeutic cancer vaccines on short- and long-term survival populations among patients with advanced lung cancer. Semin Oncol 45, 52–57.
Sanders, B., Koldijk, M., and Schuitemaker, H. (2014). Inactivated Viral Vaccines. In: Vaccine Analysis: Strategies, Principles, and Control. Berlin, Heidelberg: Springer-Verlag. 45–80.
Saunders, K.O., Lee, E., Parks, R., Martinez, D.R., Li, D., Chen, H., Edwards, R.J., Gobeil, S., Barr, M., Mansouri, K., et al. (2021). Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses. Nature 594, 553–559.
Saxena, M., van der Burg, S.H., Melief, C.J.M., and Bhardwaj, N. (2021). Therapeutic cancer vaccines. Nat Rev Cancer 21, 360–378.
Shen, J., Wang, L.F., Zou, Z.Y., Kong, W.W., Yan, J., Meng, F.Y., Chen, F. J., Du, J., Shao, J., Xu, Q.P., et al. (2017). Phase I clinical study of personalized peptide vaccination combined with radiotherapy for advanced hepatocellular carcinoma. World J Gastroenterol 23, 5395–5404.
Shimizu, Y., Suzuki, T., Yoshikawa, T., Endo, I., and Nakatsura, T. (2019). Next-generation cancer immunotherapy targeting glypican-3. Front Oncol 9, 248.
Si, L., Xu, H., Zhou, X., Zhang, Z., Tian, Z., Wang, Y., Wu, Y., Zhang, B., Niu, Z., Zhang, C., et al. (2016). Generation of influenza A viruses as live but replication-incompetent virus vaccines. Science 354, 1170–1173.
Siegel, R.L., Miller, K.D., and Jemal, A. (2020). Cancer statistics, 2020. CA Cancer J Clin 70, 7–30.
Slamon, D.J., Godolphin, W., Jones, L.A., Holt, J.A., Wong, S.G., Keith, D. E., Levin, W.J., Stuart, S.G., Udove, J., Ullrich, A., et al. (1989). Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707–712.
Smalley Rumfield, C., Pellom, S.T., Morillon II, Y.M., Schlom, J., and Jochems, C. (2020a). Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine. J Immunother Cancer 8, e000612.
Smalley Rumfield, C., Roller, N., Pellom, S.T., Schlom, J., and Jochems, C. (2020b). Therapeutic vaccines for HPV-associated malignancies. ITT 9, 167–200.
Snook, A.E., Baybutt, T.R., Xiang, B., Abraham, T.S., Flickinger, J.C., Hyslop, T., Zhan, T., Kraft, W.K., Sato, T., and Waldman, S.A. (2019). Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients. J Immunother Cancer 7, 104.
Snook, A.E., Magee, M.S., Schulz, S., and Waldman, S.A. (2014). Selective antigen-specific CD4+ T-celf but not CD8+ T- or B-celf tolerance corrupts cancer immunotherapy. Eur J Immunol 44, 1956–1966.
Sundar, R., Rha, S.Y., Yamaue, H., Katsuda, M., Kono, K., Kim, H.S., Kim, C., Mimura, K., Kua, L.F., and Yong, W.P. (2018). A phase I/Ib study of OTSGC-A24 combined peptide vaccine in advanced gastric cancer. BMC Cancer 18, 332.
Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., and Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71, 209–249.
Tait, D.R., Hatherill, M., Van Der Meeren, O., Ginsberg, A.M., Van Brakel, E., Salaun, B., Scriba, T.J., Akite, E.J., Ayles, H.M., Bollaerts, A., et al. (2019). Final analysis of a trial of M72/AS01E vaccine to prevent tuberculosis. N., Engl J Med 381, 2429–2439.
Taniguchi, M., Mizuno, S., Yoshikawa, T., Fujinami, N., Sugimoto, M., Kobayashi, S., Takahashi, S., Konishi, M., Gotohda, N., and Nakatsura, T. (2020). Peptide vaccine as an adjuvant therapy for glypican-3-positive hepatocellular carcinoma induces peptide-specific CTLs and improves long prognosis. Cancer Sci 111, 2747–2759.
Teh, M.T., Gemenetzidis, E., Chaplin, T., Young, B.D., and Philpott, M.P. (2010). Upregulation of FOXM1 induces genomic instability in human epidermal keratinocytes. Mol Cancer 9, 45.
Tissot, A.C., Maurer, P., Nussberger, J., Sabat, R., Pfister, T., Ignatenko, S., Volk, H.D., Stocker, H., Müller, P., Jennings, G.T., et al. (2008). Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. Lancet 371, 821–827.
Tkachuk, A.P., Bykonia, E.N., Popova, L.I., Kleymenov, D.A., Semashko, M.A., Chulanov, V.P., Fitilev, S.B., Maksimov, S.L., Smolyarchuk, E. A., Manuylov, V.A., et al. (2020). Safety and immunogenicity of the GamTBvac, the recombinant subunit tuberculosis vaccine candidate: a phase II, multi-center, double-blind, randomized, placebo-controlled study. Vaccines 8, 652.
Tobias, J., Jasinska, J., Baier, K., Kundi, M., Ede, N., Zielinski, C., and Wiedermann, U. (2017). Enhanced and long term immunogenicity of a Her-2/neu multi-epitope vaccine conjugated to the carrier CRM197 in conjunction with the adjuvant Montanide. BMC Cancer 17, 118.
Tovey, S.M., Reeves, J.R., Stanton, P., Ozanne, B.W., Bartlett, J.M.S., and Cooke, T.G. (2006). Low expression of HER2 protein in breast cancer is biologically significant. J Pathol 210, 358–362.
Trimble, C.L., Morrow, M.P., Kraynyak, K.A., Shen, X., Dallas, M., Yan, J., Edwards, L., Parker, R.L., Denny, L., Giffear, M., et al. (2015). Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial. Lancet 386, 2078–2088.
Trimpert, J., Adler, J.M., Eschke, K., Abdelgawad, A., Firsching, T.C., Ebert, N., Thao, T.T.N., Gruber, A.D., Thiel, V., Osterrieder, N., et al. (2021). Live attenuated virus vaccine protects against SARS-CoV-2 variants of concern B.1.1.7 (Alpha) and B.1.351 (Beta). Sci Adv 7, eabk0172.
Tsuchiya, N., Hosono, A., Yoshikawa, T., Shoda, K., Nosaka, K., Shimomura, M., Hara, J., Nitani, C., Manabe, A., Yoshihara, H., et al. (2017a). Phase I study of glypican-3-derived peptide vaccine therapy for patients with refractory pediatric solid tumors. Oncoimmunology 7, e1377872.
Tsuchiya, N., Yoshikawa, T., Fujinami, N., Saito, K., Mizuno, S., Sawada, Y., Endo, I., and Nakatsura, T. (2017b). Immunological efficacy of glypican-3 peptide vaccine in patients with advanced hepatocellular carcinoma. Oncoimmunology 6, e1346764.
Uyl-de Groot, C.A., Vermorken, J.B., Hanna, M.G., Verboom, P., Groot, M. T., Bonsel, G.J., Meijer, C.J.L.M., and Pinedo, H.M. (2005). Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits. Vaccine 23, 2379–2387.
van Cruijsen, H., Ruiz, M.G., van der Valk, P., de Gruijl, T.D., and Giaccone, G. (2009). Tissue micro array analysis of ganglioside N-glycolyl GM3 expression and signal transducer and activator of transcription (STAT)-3 activation in relation to dendritic cell infiltration and microvessel density in non-small cell lung cancer. BMC Cancer 9, 180.
Vermorken, J.B., Claessen, A.M., van Tinteren, H., Gall, H.E., Ezinga, R., Meijer, S., Scheper, R.J., Meijer, C.J., Bloemena, E., Ransom, J.H., et al. (1999). Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet 353, 345–350.
Verstraeten, T., Fletcher, M.A., Suaya, J.A., Jackson, S., Hall-Murray, C.K., Scott, D.A., Schmöle-Thoma, B., Isturiz, R.E., and Gessner, B.D. (2020). Diabetes mellitus as a vaccine-effect modifier: a review. Expert Rev Vaccines 19, 445–453.
Vignuzzi, M., Wendt, E., and Andino, R. (2008). Engineering attenuated virus vaccines by controlling replication fidelity. Nat Med 14, 154–161.
Walls, A.C., Miranda, M.C., Schäfer, A., Pham, M.N., Greaney, A., Arunachalam, P.S., Navarro, M.J., Tortorici, M.A., Rogers, K., O’Connor, M.A., et al. (2021). Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines. Cell 184, 5432–5447.e16.
Wang, W., Pan, D., Fu, W. et al. Development of a skin- and neuro-attenuated live vaccine for varicella. Nat Commun 13, 824 (2022).
Wang, T.Y., Wang, L., Alam, S.K., Hoeppner, L.H., and Yang, R. (2019). ScanNeo: identifying indel-derived neoantigens using RNA-Seq data. Bioinformatics 35, 4159–4161.
Wang, Y., Yang, C., Song, Y., Coleman, J.R., Stawowczyk, M., Tafrova, J., Tasker, S., Boltz, D., Baker, R., Garcia, L., et al. (2021). Scalable live-attenuated SARS-CoV-2 vaccine candidate demonstrates preclinical safety and efficacy. Proc Natl Acad Sci USA 118, e2102775118.
Ward, B.J., Gobeil, P., Séguin, A., Atkins, J., Boulay, I., Charbonneau, P.Y., Couture, M., D’Aoust, M.A., Dhaliwall, J., Finkle, C., et al. (2021). Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19. Nat Med 27, 1071–1078.
Watson, S.A., and Gilliam, A.D. (2001). G17DT—a new weapon in the therapeutic armoury for gastrointestinal malignancy. Expert Opin Biol Ther 1, 309–317.
Wei, L., Zhao, T., Zhang, J., Mao, Q., Gong, G., Sun, Y., Chen, Y., Wang, M., Tan, D., Gong, Z., et al. (2022). Efficacy and safety of a nanoparticle therapeutic vaccine in patients with chronic hepatitis B: a randomized clinical trial. Hepatology 75, 182–195.
Wiedermann, U., Garner-Spitzer, E., Chao, Y., Maglakelidze, M., Bulat, I., Dechaphunkul, A., Arpornwirat, W., Charoentum, C., Yen, C.J., Yau, T. C., et al. (2021). Clinical and immunologic responses to a B-cell epitope vaccine in patients with HER2/neu-overexpressing advanced gastric cancer—results from phase Ib trial IMU.ACS.001. Clin Cancer Res 27, 3649–3660.
Willson, J. (2020). Vaccinology in reverse (Nature).
Wrobel, P., and Ahmed, S. (2019). Current status of immunotherapy in metastatic colorectal cancer. Int J Colorectal Dis 34, 13–25.
Wu, H., Wang, Y., Wang, G., Qiu, Z., Hu, X., Zhang, H., Yan, X., Ke, F., Zou, A., Wang, M., et al. (2020). A bivalent antihypertensive vaccine targeting L-type calcium channels and angiotensin AT1 receptors. Br J Pharmacol 177, 402–419.
Xu, D.Z., Wang, X.Y., Shen, X.L., Gong, G.Z., Ren, H., Guo, L.M., Sun, A. M., Xu, M., Li, L.J., Guo, X.H., et al. (2013). Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findings. J Hepatol 59, 450–456.
Xu, K., Acharya, P., Kong, R., Cheng, C., Chuang, G.Y., Liu, K., Louder, M.K., O’Dell, S., Rawi, R., Sastry, M., et al. (2018). Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1. Nat Med 24, 857–867.
Yarchoan, M., Johnson III, B.A., Lutz, E.R., Laheru, D.A., and Jaffee, E.M. (2017). Targeting neoantigens to augment antitumour immunity. Nat Rev Cancer 17, 209–222.
Yeh, M.T., Bujaki, E., Dolan, P.T., Smith, M., Wahid, R., Konz, J., Weiner, A.J., Bandyopadhyay, A.S., Van Damme, P., De Coster, I., et al. (2020). Engineering the live-attenuated polio vaccine to prevent reversion to virulence. Cell Host Microbe 27, 736–751.e8.
Yoshino, T., Arnold, D., Taniguchi, H., Pentheroudakis, G., Yamazaki, K., Xu, R.H., Kim, T.W., Ismail, F., Tan, I.B., Yeh, K.H., et al. (2018). Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Ann Oncol 29, 44–70.
Yu, M., Chi, X., Huang, S., Wang, Z., Chen, J., Qian, C., Han, F., Cao, L., Li, J., Sun, H., et al. (2022). A bacterially expressed triple-type chimeric vaccine against human papillomavirus types 51, 69, and 26. Vaccine 40, 6141–6152.
Zeitlinger, M., Bauer, M., Reindl-Schwaighofer, R., Stoekenbroek, R.M., Lambert, G., Berger-Sieczkowski, E., Lagler, H., Oesterreicher, Z., Wulkersdorfer, B., Lührs, P., et al. (2021). A phase I study assessing the safety, tolerability, immunogenicity, and low-density lipoprotein cholesterol-lowering activity of immunotherapeutics targeting PCSK9. Eur J Clin Pharmacol 77, 1473–1484.
Zhang, N.N., Li, X.F., Deng, Y.Q., Zhao, H., Huang, Y.J., Yang, G., Huang, W.J., Gao, P., Zhou, C., Zhang, R.R., et al. (2020). A thermostable mRNA vaccine against COVID-19. Cell 182, 1271–1283.e16.
Acknowledgements
This work was supported by the National Key Research and Development Program of China (2021YFC2301404), the National Natural Science Foundation of China (81991490, 82001756), the Health Education Joint Project of Fujian Province (2019-WJ-05), the President Foundation of Xiamen University (20720200062), and CAMS Innovation Fund for Medical Sciences of China (2019RU022).
Author information
Authors and Affiliations
Corresponding authors
Additional information
Compliance and ethics
The author(s) declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Li, T., Qian, C., Gu, Y. et al. Current progress in the development of prophylactic and therapeutic vaccines. Sci. China Life Sci. 66, 679–710 (2023). https://doi.org/10.1007/s11427-022-2230-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11427-022-2230-4